ArticleJournal of health economics and outcomes research2019

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom.

Gaurav Suri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.